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Abstract
Background: Identification of fibroblast derived factors in tumor progression has the potential to
provide novel molecular targets for modulating tumor cell growth and metastasis. Multiple matrix
metalloproteases (MMPs) are expressed by both mesenchymal and epithelial cells within head and
neck squamous cell carcinomas (HNSCCs), but the relative importance of these enzymes and the
cell source is the subject of controversy.
Methods: The invasive potential of HNSCC tumor cells were assessed in vitro atop type I collagen
gels in coculture with wild-type (WT), MMP-2 null, MMP-9 null or MT1-MMP null fibroblasts. A
floor of mouth mouse model of HNSCC was used to assess in vivo growth after co-injection of
FaDu tumor cells with MMP null fibroblasts.
Results: Here we report changes in tumor phenotype when FaDu HNSCCs cells are cocultured
with WT, MMP-2 null, MMP-9 null or MT1-MMP null fibroblasts in vitro and in vivo. WT, MMP-2
null and MMP-9 null fibroblasts, but not MT1-MMP null fibroblasts, spontaneously invaded into type
I collagen gels. WT fibroblasts stimulated FaDu tumor cell invasion in coculture. This invasive
phenotype was unaffected by combination with MMP-9 null fibroblasts, reduced with MMP-2 null
fibroblasts (50%) and abrogated in MT1-MMP null fibroblasts. Co-injection of FaDu tumor cells with
fibroblasts in an orthotopic oral cavity SCID mouse model demonstrated a reduction of tumor
volume using MMP-9 and MMP-2 null fibroblasts (48% and 49%, respectively) compared to WT
fibroblasts. Consistent with in vitro studies, MT1-MMP null fibroblasts when co-injected with FaDu
cells resulted in a 90% reduction in tumor volume compared to FaDu cells injected with WT
fibroblasts.
Conclusion: These data suggest a role for fibroblast-derived MMP-2 and MT1-MMP in HNSCC
tumor invasion in vitro and tumor growth in vivo.
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Background
The mass of solid epithelial tumor is composed not only
of malignant epithelial cells, but also of fibroblasts,
endothelial cells and inflammatory cells that in theory,
can contribute to tumor cell growth and metastatic
spread. Matrix metalloproteinase (MMP) expression by
tumor cells and surrounding stromal cell types is thought
to contribute to tumor progression, although the relative
importance of fibroblast-derived proteases remains the
subject of speculation. Expression of MMPs has been
identified in both the epithelial and stromal elements of
head and neck squamous cell carcinoma (HNSCC) [1].
Tumor cell interaction with surrounding fibroblasts is
thought to generate a microenvironment favorable for
tumor growth and invasion and promote MMP expres-
sion [2]. Identifying which MMPs are critical for tumor
progression remains a prerequisite for development of tar-
geted molecular therapy [3]. Because MMP-2, MMP-9 and
MT1-MMP are frequently identified in the stromal tissues
within HNSCC [4-6], and expression of these enzymes
shown to correlate with patient outcome [1,4,7], we
examined the role of fibroblast derived MMP-2, MMP-9
and MT1-MMP. Using an in vitro collagen invasion model
and an orthotopic model of tumor growth, we identified
a role for MMP-2 and MT1-MMP in tumor growth and
invasion.
Methods
Cell culture
The FaDu cell line was purchased from American Type Tis-
sue Collection (Manassas, VA). Fibroblasts were isolated
from the dermis of late gestation embryos in mice defi-
cient in MT1-MMP[8], MMP-2 [9] and MMP-9 [10]. Mice
strains were outbred Black Swiss. Fibroblasts derived from
both backgrounds (littermates) were used as control.
Fibroblasts were used between passages 2–6 and main-
tained in DMEM supplemented with 10% (v/v) fetal
bovine serum (Mediatech, Herdon, VA) and antibiotics
(100 units/ml penicillin and 100 ug/ml streptomycin sul-
phate, Mediatech). There was one fibroblast preparation
for each of the MMP null cell lines that were used in the
in vivo and in vitro experiments. There were two wild type
fibroblast cell lines isolated and used to confirm the in
vitro and in vivo experiments. Cell lines were maintained
in DMEM supplemented with 10% (v/v) fetal bovine
serum (Mediatech), 2 mM L-glutamine and antibiotics
(100 units/ml penicillin and 100 ug/ml streptomycin sul-
phate). Human recombinant TIMP-1 (Calbiochem, San
Diego, CA) and TIMP-2 (R&D Systems) were used for
MMP inhibition and serine protease inhibitors leupeptin
and epsilon-amino-caproic acid (EACA) were obtained
from Sigma (St Louis, MO). E64 (Sigma), deconyl-Arg-
Val-Lys-Arg-CMK (Alexis Biochemicals, San Diego, CA),
and GM6001 (Calbiochem) were also added to the inva-
sion assay.
Invasion assays
Type I collagen (0.9 ml) was prepared as described [11]
and added to the Costar Transwell dishes (Corning, Inc.,
Corning, NY). A final concentration of 3.0 mg/ml was
obtained. Media was then added to the upper and lower
chamber prior to the addition of 2 × 105 tumor cells/well
and/or 5 × 105 fibroblasts. Consistent with the nature of
primary cell culture [12], the fibroblasts grew at different
rates relative to wild-type (MMP-2 83%, MMP-9 88%,
MT1-MMP 90%). To compensate for the potential nega-
tive impact of this growth rate both a 1:2 ratio and a 1:3
ratio of tumor cells to fibroblasts was used for each fibrob-
last type to compensate for variations in primary culture
growth rate [12]. Invasion assays were performed in either
FBS or mouse serum-containing medium (derived from
either wild-type, MMP-2-/- or MMP9-/- mice). MMP-2
null serum was used for MMP-2 null experiments since
MMP-2 is produced in the serum. Failure to do this would
allow contamination of the experiment with MMP-2 con-
taining serum. Similarly, MMP-9 null serum was used in
MMP-9 null experiments. MT1-MMP is not present in nor-
mal serum.
Sample fixation and processing
Gels were removed from the Transwell dish after the 6 day
incubation period and then placed in 2.7% formaldehyde
and embedded in paraffin. Sections (6-um) were cut and
stained with hematoxylin and eosin. Tumor cell invasion
was assessed by light microscopy in a minimum of four
randomly selected sections for each experimental sample.
In this assay the number of invading cells was normalized
to the total number of cells (surface and invading). The
unpaired t-test was used to compare means.
Immunohistochemical methods
Immunohistochemistry of paraffin embedded sections
was performed as previously described [13]. Primary
EMMPRIN antibody (Zymed Laboratories, Inc, San Fran-
cisco, CA; 1 µg/ml) was used on deparaffinized and rehy-
drated sections of the type I collagen invasion assay
without antigen retrieval. Immunoreactivity was con-
firmed by assessing the staining with a second EMMPRIN
antibody (BD Biosciences, Franklin Lakes, NJ; OX-47 at 2
ug/ml) on consecutive sections.
In vivo tumor studies
Severe combined immune deficiency (SCID) male mice
were obtained (Charles River, Wilmington, MA) and han-
dled in accordance with the institution's IACUC guide-
lines. Under sterile technique, 4 × 105 cells FaDu cells with
or without fibroblasts (0.015 ml volume) were injected
transcervically into the tongue musculature. At this inocu-
lum, FaDu cells will not consistently form tumors in the
absence of fibroblasts. To compensate for variations in
fibroblast growth rate, the ratio of tumor cells to fibrob-BMC Cancer 2006, 6:52 http://www.biomedcentral.com/1471-2407/6/52
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lasts was assessed at 1:2 and 1:3. Each animal group con-
tained at least 9 animals. Ultrasound measurements were
performed using a 55 MHz-based radial probe (Visual-
Sonic, Toronto, Canada) at 10 days under anesthesia and
the area of greatest diameter in the coronal plane was
found and each tumor size was determined by measuring
the greatest coronal cross-section in two dimensions. At
14 days, tumors were resected with the mandible intact,
MT1-MMP deficient fibroblasts demonstrate reduced invasion into type I collagen gels Figure 1
MT1-MMP deficient fibroblasts demonstrate reduced invasion into type I collagen gels. Wild-type (WT) murine fibroblasts 
derived from the dermis of late-gestation embryos were cultured atop collagen and invasion assessed over a 6 day period in 
the presence or absence of TIMP-2 (10 nM) added to the culture daily (A). MMP-2 -/- and MMP-9 -/-, but not MT1-MMP -/- 
cells penetrate type I collagen over the 6 day culture period normalized for total cell number (B); the results are quantified by 
number of cells invading and depth of penetration (C). Experiments were conducted in DMEM with 10% WT, MMP-2 null or 
MMP-9 null serum. (Magnification as marked, bar = 100 µm)BMC Cancer 2006, 6:52 http://www.biomedcentral.com/1471-2407/6/52
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decalcified and processed for histology. Serial sections of
the specimen were then cut and stained with hematoxylin
and eosin and the tumor volume calculated.
Results
In vitro invasion of murine fibroblasts
Consistent with other reports that have identified the
importance of MT1-MMP in remodeling of type I collagen
matrices [8,14], we hypothesized that MT1-MMP deficient
fibroblasts would be unable to invade type I collagen
matrices. Wild-type (WT) fibroblasts were found to invade
into type I collagen gels in vitro over the 6 day incubation
period (Figure 1A). Invasion was inhibited by tissue
inhibitor of metalloproteinase, TIMP-2, and the broad
spectrum synthetic MMP inhibitor, GM6001. While
MMP-9 and MMP-2 deficient fibroblasts retained an inva-
sive phenotype over the 7 day culture period, MT1-MMP
null fibroblasts failed to penetrate the matrix (Fig. 1C).
Although fewer cells penetrated the matrix for the MMP-2
and MMP-9 null fibroblasts (p < 0.05), the depth of pen-
etration was the same (Figure 1D). MT1-MMP null fibrob-
lasts had lower penetration into collagen gel compared to
WT, MMP-2 null and MMP-9 null fibroblasts.
Wild-type murine fibroblasts induce MMP-dependent 
invasion in vitro
WT murine fibroblasts were cocultured with human
tumor cells in a 2:1 or 3:1 ratio with human head and
neck squamous cell (HNSCC) tumor cells atop type I col-
lagen over a 6 day incubation period. The fibroblasts
induced significant invasion of tumor cells into the matrix
(Fig. 2A). A tumor cell:fibroblast ratio of 1:2 or 1:3 was
Coculture of FaDu tumor cells and wild-type (WT) fibroblasts induces MMP-dependent tumor cell invasion Figure 2
Coculture of FaDu tumor cells and wild-type (WT) fibroblasts induces MMP-dependent tumor cell invasion. WT fibroblasts 
were cultured in a 2:1 ratio with FaDU HNSCC tumor cells atop Type I collagen for 6 days. EMMPRIN immunoreactivity iden-
tified invading tumor cells (A). Protease inhibitors were added to assess the role of MMPs in the invasive program (B). FaDu-
WT fibroblast invasion was sensitive to synthetic (GM6001, 20 uM) and endogenous (TIMP2, 10 nM) broad spectrum MMP 
inhibitors and to furin inhibition (synthetic peptidyl chloromethyl ketones, CMK, 50 uM), but not TIMP-1 (10 nM), serine pro-
tease inhibitors (leupeptin, 10 uM; epsilon-amino-caproic acid (EACA), 10 mM) or cysteine protease inhibitors (E64, 10 ug/ml). 
Bar, 100 µm.BMC Cancer 2006, 6:52 http://www.biomedcentral.com/1471-2407/6/52
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used, but the ratio of cells did not alter the phenotype
(data not shown). The high levels of EMMPRIN expres-
sion in HNSCC tumors, but not in fibroblasts [13], was
used to identify invading tumor cells in the matrix. Syn-
thetic (GM6001, 20 uM) and endogenous (TIMP-2, 10
nM) broad spectrum MMP inhibitors were able to inhibit
tumor cell invasion into the matrix (Fig. 2B). Inhibition of
furin, which processes MT1-MMP to its active form intra-
cellularly, by CMK (50 uM) blocked invasion, but not
addition of TIMP-1 which is a poor inhibitor of mem-
brane anchored MMPs [15]. Serine protease inhibitors
(leupeptin, 10 uM; epsilon-amino-caproic acid (EACA),
10 mM) or cysteine protease inhibitors (E64, 10 ug/ml)
did not decrease tumor cell invasion.
MT1-MMP deficient fibroblasts fail to promote in vitro 
invasion
To assess whether fibroblast derived MMP-2, MMP-9 or
MT1-MMP can promote tumor cell invasion in vitro, the
murine fibroblasts were cocultured with human FaDu
tumor cells (Fig. 3A and 3B). Because of variations in
fibroblast growth rates, cocultures were performed at 2:1
and 3:1 (fibroblast:tumor cell) with similar results (results
for 2:1 WT:FaDu and 3:1 MMP null:FaDu cells shown).
Unlike the fibroblast invasion assay alone, FaDu tumor
cells in coculture with MMP-2 null fibroblasts demon-
strated 50% less invasion compared to FaDu cells in coc-
ulture with MMP-9 null or WT fibroblasts. This finding
suggests a role for MMP-2 in the more complex model of
tumor cell invasion. Although FaDu tumor cells express
MT1-MMP (data not shown), MT1-MMP null fibroblasts
failed to promote FaDu tumor cell invasion. This suggests
that localization of this enzyme to fibroblasts induces
tumor cell invasion. Incubation of sub-confluent FaDu
tumor cells atop type I collagen with serum-free condi-
tioned media from WT, MMP-2 null, MMP-9 null or MT1-
MMP null fibroblasts failed to induce FaDU tumor cell
invasion (data not shown) over a 7 day incubation period.
Decreased tumor cell invasion induced by MMP-2 and MT1-MMP null fibroblasts in vitro Figure 3
Decreased tumor cell invasion induced by MMP-2 and MT1-MMP null fibroblasts in vitro. The human FaDu HNSCC tumor cell 
line was cultured alone or in combination with WT, MMP-2 null, MMP-9 null, or MT1-MMP null fibroblasts atop type I collagen 
for 6 days (A, and quantified in B). Experiments were conducted in DMEM with 10% WT, MMP-2 null or MMP-9 null serum. 
Gelatin zymography of 18-hour serum free conditioned media from FaDu tumor cells in coculture with fibroblasts atop colla-
gen (2:1 ratio) normalized for cell-number.BMC Cancer 2006, 6:52 http://www.biomedcentral.com/1471-2407/6/52
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In vivo growth of FaDu cells co-injected with murine fibroblasts Figure 4
In vivo growth of FaDu cells co-injected with murine fibroblasts. FaDu tumor cells (4 × 105 cells) were injected transcervically 
into the oral cavity of SCID mice alone or in combination with WT fibroblasts (8 × 105), MMP-2 null, MMP-9 null or MT1-MMP 
fibroblasts (8 × 105 (data not shown) or 1.2 × 106 cells). Measurements of tumor growth were taken at 10 days by ultrasound 
examination and at 14 days by histological sectioning of the mandible-tongue complex in the coronal plane (bar is 1 mm in 
coronal sections or 100 µM in histology) (A). Greatest cross sectional tumor area measurements were compared (B) for both 
groups. C, percent tumor formation in the orthotopic SCID mouse model over the two week observation period was equal to 
the number of tumors formed divided by number of mice (one injection per mouse with least 10 mice were injected per 
group).BMC Cancer 2006, 6:52 http://www.biomedcentral.com/1471-2407/6/52
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Analysis of conditioned media obtained from cells cocul-
tured on type I collagen demonstrates that fibroblasts and
not tumor cells express proMMP-2 and MMP-9 (Fig. 3C).
In vivo growth of tumors injected with WT or MMP null 
fibroblasts
To examine the effects of MMP derived fibroblasts in vivo,
FaDu tumor cells were injected alone or in combination
with WT, MMP-2 null, MMP-9 null, or MT1-MMP null
fibroblasts into the oral cavity of SCID mice in ratios of
1:2 and 1:3 (tumor cell:fibroblast). Fibroblasts injected
alone did not form tumors. Tumors were assessed at 10
days by ultrasound examination and then at 14 days by
histological serial sectioning (Fig. 4A). Assessment of
tumor histology, tumor grade, invasive edge,
stroma:tumor ratio, or microvessel density did not reveal
any consistent differences between groups (data not
shown). The FaDu inoculum of tumor cells (4 × 105) in
this orthotopic mouse model failed to generate tumors in
40% of mice injected with FaDu cells alone. Consistent
with other reports that identify the growth promoting
effects of co-injecting fibroblasts with HNSCC cells [16],
co-injection of FaDu cells with WT fibroblasts resulted in
100% tumor formation. Interestingly, the MMP-9 null
fibroblast had reduced in vivo effect on FaDu tumor
growth compared to WT fibroblasts (48% less tumor vol-
ume) despite the absence of observed differences for
MMP-9 null fibroblasts in previous in vitro experiments.
The reduced influence of MMP-2 null fibroblasts on FaDu
tumor invasion in vitro and growth in vivo (49% less
tumor volume) remained consistent. Smaller tumors were
formed when FaDu tumor cells were co-injected with
MT1-MMP deficient fibroblasts as compared either MMP-
2 null (80% smaller) or MMP-9 null (80% smaller) or WT
fibroblasts (92% smaller). However, MMP-2 null and
MMP-9 null fibroblasts combined with FaDu tumor cells
formed significantly larger tumors than FaDu cells
injected alone (p = 0.04 and 0.009, respectively). MT1-
MMP remained critical for the positive growth effect of co-
injected fibroblasts with reduced tumor size (p = 0.0001,
compared with WT and FaDu cells) and incidence of for-
mation. Although MMP-2 null and MMP-9 null fibrob-
lasts formed smaller tumors in vivo, the take rate for these
fibroblasts in combination with tumor cells was 100% of
injected animals (Fig. 4C). MT1-MMP fibroblasts com-
bined with tumor cells failed to form tumors in 30% of
injections, which approached statistical significance when
compared to coinjection with WT fibroblasts (p = 0.08).
Discussion
Recent attempts to understand tumor growth have
focused on the surrounding stroma which is considered
important in epithelial transformation, cellular invasion
and tumor growth [17,18]. The importance of MMPs in
tumor cell migration through the extracellular matrix has
been established [2,12,19-21], even if the cellular source
of the proteases remains uncertain. Our results suggest the
importance of fibroblast-derived MT1-MMP and MMP-2
in head and neck squamous cell carcinoma cell invasion
in vitro and tumor cell growth in vivo.
The growth promoting effects of fibroblasts in multiple
tumor types has been demonstrated [22,23], including in
HNSCC cell lines [16]. Indeed, fibroblasts promote
growth in MCF7 cells in vivo that can be inhibited with
TIMP-2 or synthetic MMP inhibitor [24]. Cocultures of
FaDu cells and MT1-MMP null fibroblasts dramatically
abrogated the effect of WT fibroblasts in promoting FaDu
tumor cell invasion in vitro and tumor growth in vivo sug-
gesting a prominent role for this enzyme. This data is con-
sistent with the importance of membrane type-1 MMP
(MT1-MMP) in physiological processes such post-natal
murine development [8] and in single cell in vitro inva-
sion [14]. MT1-MMP is expressed in both tumor cells and
fibroblasts [1,25].
The significance of MT1-MMP expression in tumor cells
has convincingly demonstrated that overexpression of
MT1-MMP in tumor cells promotes growth [26]. The data
presented here examines the influence of fibroblast
derived MT1-MMP during tumor invasion into type I col-
lagen and tumor growth in vivo. Although it is known that
MT1-MMP is expressed by the tumor cell (as well the
fibroblast), the cell source of this membrane bound pro-
tein may determine function. We demonstrated that in an
in vitro setting that fibroblast-derived, but not tumor cell
derived, MT1-MMP was responsible for type I collagen
degradation [27]. Although all in vitro invasion assays
were conducted in the presence of serum, additional
growth factors were not required to induce invasion when
tumor cells were combined with fibroblasts. Indeed, it
may be that MMP-dependent cleavage of growth factors
combined with reciprocal signaling between tumor cell
and fibroblast promotes invasion. The mechanism of
MT1-MMP activity in this process requires additional
studies to determine whether MT1-MMP expression in
fibroblasts disrupts cell-cell signaling, cell growth, tumor
cell invasion, and/or promotes matrix degradation.
Our data suggest a role for MMP-2 during in vitro invasion
and MMP-9 and MMP-2 during in vivo tumor cell growth.
Although it would be more convenient, it is not surprising
that more than a single protease enables tumor cell migra-
tion through extracellular matrix barriers or growth, par-
ticularly in complex models of tumor cell invasion or
growth. Indeed, with increasing complexity of the model
system, the importance of MMP-2 and MMP-9 became
apparent. MMP-2 null fibroblast invasion was compara-
ble to wild-type in the absence of tumor cells, but MMP-2
deficient fibroblasts cocultured with FaDu tumor cellsBMC Cancer 2006, 6:52 http://www.biomedcentral.com/1471-2407/6/52
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decreased in vitro invasion by almost 50%. Others have
failed to identify a role for MMP-2 in a type I collagen in
vitro assay assessing endothelial cell invasion [28]. Unlike
this study and others that assay invasion using a single cell
type [14], we report that in tumor-mesenchymal cell co-
culture multiple MMPs may play a role in the invasive
program. In the in vivo setting, both MMP-2 and MMP-9
null fibroblasts decreased FaDu tumor volume compared
to wild-type fibroblasts, but MMP-2 and MMP-9 null
fibroblasts promoted 100% tumor formation. The effect
of these two enzymes is likely under represented by this
model. While the oral cavity SCID mouse model of
HNSCC requires less than 7 days to obtain measurable
tumors, providing limited time for in growth of surround-
ing tissue, it is possible that the elaboration of secreted
MMPs by surrounding tissues and the presence of MMP-2
and MMP-9 in the serum prevent formation of a tumor
microenvironment devoid of MMP-2 or MMP-9.
Thus, loss of MT1-MMP consistently decreased the inva-
sion or growth promoting influence of fibroblasts in vivo
and in vitro and loss of MMP-2 and MMP-9 altered tumor
growth with increasing complexity of the model system.
Because MT1-MMP is known to activate MMP-2, reduced
tumor cell invasion and tumor growth demonstrated in
coculture experiments with MT1-MMP null fibroblasts
may in part result from a failure to activate pro-MMP-2.
However, since loss of MMP-2 produced more subtle phe-
notypic changes, fibroblast-derived MT1-MMP must have
alternate enzymatic targets. Because recent evidence sug-
gests that MT1-MMP (but not MMP-2 or MMP-9) express
proteolytic activity that mediates fibroblast migration
through type I collagen [14] and MMP-2 and MMP-9 defi-
cient mice develop normally, it is possible that MMP-2 or
MMP-9 play a role in more complex models of tumor
invasion or growth because they disrupt tumor-stromal
signaling rather than matrix degradation. Indeed, there is
significant work to suggest a role for both these enzymes
in tumor-stromal signaling [2,12].
It is unlikely that that this signaling mechanism involved
an alteration in neovascularization. Histological exam of
xenografted tumors did not demonstrate differences in
microvessel density or histology (Figure 4 and data not
shown). These results should be interpreted with caution
as the significance of microvessel density remains unclear
in HNSCC. In head and neck cancer, microvessel density
is not associated with clinicopathological features [29].
It remains unclear why host derived MMPs from the
serum or surrounding fibroblasts did not compensate for
injected MMP null fibroblasts. This is most likely because
of the rapid growth of the tumor over a one week period,
not allowing a significant influence from surrounding
cells. It is possible that the host MMPs did partially com-
pensate (e.g., the reduced growth rate of MMP-2 and
MMP-9 null fibroblasts compared to wild-type fibroblasts
cocultured with FaDu cells in vivo represents a host com-
pensation for an otherwise more significant effect). How-
ever, despite the potential influence of host MMPs, the
tumor volume was still reduced in both experimental
groups, suggesting that fibroblast derived MMP-2 and
MMP-9 promote tumor cell growth in vivo. Given the
results of our in vitro studies, these enzymes may play a
complex role in the tumor-stromal signaling, rather than
matrix degradation. In other reports, human xenografts in
MMP-2 deficient mice demonstrated a 39% reduction in
growth, respectively [9]. This is consistent with our
decreased growth rate.
The results of these studies suggest that fibroblast derived
MT1-MMP promotes tumor cell invasion and growth.
There were no morphological differences between in vivo
tumors in microvascular density, invasive pattern or stro-
mal density to suggest a possible explanation for the dif-
ferential rate of tumor growth. Because in vitro results
(decreased invasion) may not translate to the phenotype
measured in vivo (decreased growth), addressing the
mechanism in vitro will not necessarily predict results in
vivo. The mechanism by which fibroblast derived MT1-
MMP promotes tumor growth is under investigation in
our lab. These results have not been previously demon-
strated in two cell system or in vivo. The failure of MMP
inhibitors in prior phase III clinical trials has been widely
considered a failure to understand the complex biology of
MMPs in tumor progression [3]. These results suggest that
targeted MT1-MMP therapy may limit tumor cell growth
and metastasis.
Conclusion
Collectively, these data suggest a role for fibroblast-
derived MMP-2 and MT1-MMP in HNSCC tumor inva-
sion in vitro and tumor growth in vivo.
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